- Moolec Science SA Regains Compliance with All Nasdaq Capital Market Continued Listing Requirements Within Panel Remediation Period
May 13, 2026 · accessnewswire.com
GEORGE TOWN, CAYMAN ISLANDS / ACCESS Newswire / May 13, 2026 / As previously reported on January 29, 2026, Moolec Science SA ("Moolec" and/or the "Company"), received written notice from the Nasdaq Hearings Panel (the "Panel") informing the Company that the Panel had granted the Company's request for an extension to regain compliance with the continued listing requirements of The Nasdaq Stock Market LLC, specifically with respect to the minimum stockholders' equity requirement. The Company announced today that it has submitted information required to demonstrate compliance with the Nasdaq Capital Market's stockholders' equity requirement within the remediation period granted by the Panel.
- MOOLEC SCIENCE SA REGAINS COMPLIANCE WITH ALL NASDAQ CAPITAL MARKET CONTINUED LISTING REQUIREMENTS WITHIN PANEL REMEDIATION PERIOD
May 13, 2026
GEORGE TOWN, CAYMAN ISLANDS / ACCESS NEWSWIRE / MAY 13, 2026 / AS PREVIOUSLY REPORTED ON JANUARY 29, 2026, MOOLEC SCIENCE SA ("MOOLEC" AND/OR THE "COMPANY"), RECEIVED WRITTEN NOTICE FROM THE NASDAQ HEARINGS PANEL (THE "PANEL") INFORMING THE COMPANY THAT THE PANEL HAD GRANTED THE COMPANY'S REQUEST FOR AN EXTENSION TO REGAIN COMPLIANCE WITH THE CONTINUED LISTING REQUIREMENTS OF THE NASDAQ STOCK MARKET LLC, SPECIFICALLY WITH RESPECT TO THE MINIMUM STOCKHOLDERS' EQUITY REQUIREMENT. THE COMPANY ANNOUNCED TODAY THAT IT HAS SUBMITTED INFORMATION REQUIRED TO DEMONSTRATE COMPLIANCE WITH THE NASDAQ CAPITAL MARKET'S STOCKHOLDERS' EQUITY REQUIREMENT WITHIN THE REMEDIATION PERIOD GRANTED BY THE PANEL.
- Helix Biopharma Corp. Announces Strategic Board and Governance Appointments to Support Financing and Nasdaq Uplisting Strategy
May 13, 2026 · thenewswire.com
Toronto, Ontario – TheNewswire - 13 May, 2026 – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, is pleased to announce the following appointments, effective immediately: Zachary T. Stadnyk, former TSX Life Sciences Lead and a biotech capital markets executive, has been appointed to the Company's Board of Directors (the “Board” ), and Natalia L. Butterworth, Director, Corporate Secretarial and Governance at ARO Consulting Inc., has been appointed Corporate Secretary of the Company. Mr. Stadnyk brings more than 15 years of experience across biotechnology, capital markets, and public company leadership, including serving as Head of Life Sciences at the TSX and TSXV, where he advised biotech issuers, boards and institutional investors on public listings, capital formation and strategic positioning, with deep experience in public market execution. Over the course of his career, he has led and supported over $100 million in institutional financings, contributed to strategic transactions including the $435 million acquisition of The Supreme Cannabis Company by Canopy Growth, and advised public companies across the biotech, healthcare and AI sectors.
- Is CME Group Expanding Into the Compute Futures Market?
May 13, 2026
CME Group Inc. CME is expanding its presence in next-generation financial markets through a partnership with Silicon Data, which is backed by global trading firm DRW, to launch a first-of-its-kind compute futures market later this year, pending regulatory approval. The initiative highlights CME’s strategy to capitalize on the rapidly growing AI infrastructure economy by introducing risk-management tools tied to compute and GPU pricing.
The new futures contracts will be based on Silicon Data’s daily GPU benchmark indices for on-demand rental rates, allowing traders, financial institutions, AI developers and cloud-service providers to manage volatility and price risk in the expanding compute market. As demand for GPUs and AI infrastructure continues to surge, pricing across compute markets has remained fragmented and volatile due to differences among providers, regions and contract structures.
By introducing standardized futures tied to transparent benchmark pricing, CME brings the scale, market structure and credibility needed to help transform compute from an opaque operational cost into a more mature and risk-manageable financial market. The launch of compute futures is an important step toward giving AI builders, cloud providers and investors more reliable tools for valuation, hedging and long-term planning as demand for compute continues to accelerate.
The development aligns with CME Group’s strategy to expand into emerging asset classes tied to rising AI and cloud infrastructure demand. Growing adoption of compute futures could drive higher trading volumes, clearing activity and revenue diversification over time while strengthening CME’s position in evolving derivatives markets.
How Are Competitors Faring?
Peers like Nasdaq, Inc. NDAQ and London Stock Exchange Group plc LSEGY are also increasing investments in next-generation financial infrastructure through strategic technology partnerships.
Nasdaq has expanded its collaboration with Amazon Web Services to modernize global capital markets infrastructure, cloud-enabled trading systems and AI-powered market solutions. The partnership reflects Nasdaq’s broader strategy to build scalable and resilient financial ecosystems capable of supporting future trading and data demands driven by AI and cloud adoption.
LSEGY has strengthened its partnership with Amazon Web Services to migrate more of its markets, risk intelligence and analytics infrastructure to the cloud. The move is aimed at improving resilience, accelerating product innovation and enhancing large-scale data and risk analysis capabilities.
Story Continues
CME’s Price Performance, Valuation & Estimates
Shares of CME have risen 6.5% over the past year against the industry's decline of 6.9%.Zacks Investment Research
Image Source: Zacks Investment Research
From a valuation standpoint, CME Group trades at a forward price-to-earnings ratio of 22.97X, up from the industry average of 20.90X.Zacks Investment Research
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for CME Group’s 2026 earnings is pegged at $12.26 per share, implying a 9.5% jump from the year-ago period.Zacks Investment Research
Image Source: Zacks Investment Research
CME currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CME Group Inc. (CME) : Free Stock Analysis Report
Nasdaq, Inc. (NDAQ) : Free Stock Analysis Report
London Stock Exchange Group plc - Unsponsored ADR (LSEGY) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- Is NDAQ Overvalued? DCF Says Worth $68
May 13, 2026 · gurufocus.com
On May 13, 2026, we present a detailed DCF analysis for Nasdaq Inc (NDAQ), a company currently trading at $89.49. Despite a modest one-year price increase of 11
- Palvella Therapeutics Announces Uplisting to the Nasdaq Global Market
May 13, 2026 · globenewswire.com
Uplisting reflects Palvella's continued progress advancing potential first-in-disease therapies for serious, rare skin diseases and vascular malformations
- PALVELLA THERAPEUTICS ANNOUNCES UPLISTING TO THE NASDAQ GLOBAL MARKET
May 13, 2026
UPLISTING REFLECTS PALVELLA'S CONTINUED PROGRESS ADVANCING POTENTIAL FIRST-IN-DISEASE THERAPIES FOR SERIOUS, RARE SKIN DISEASES AND VASCULAR MALFORMATIONS
- New QVOL ETF Targets High Monthly Income via Nasdaq
May 12, 2026 · etftrends.com
On Tuesday, May 12, Infrastructure Capital Advisors announced the debut of the Infrastructure Capital Nasdaq Option Income ETF (QVOL). QVOL is an actively managed fund that aims to generate high monthly income via options premiums.
- Nasdaq Stock Outlook: Is Wall Street Bullish or Bearish?
May 12, 2026
New York-based Nasdaq, Inc. (NDAQ) operates as a technology company that serves capital markets and other industries worldwide. Valued at $50 billion by market cap, the company provides trading, clearing, exchange technology, regulatory, securities listing, analysis, investing tools and guides, financial, and information services.
Shares of this leading global technology company have underperformed the broader market over the past year. NDAQ has gained 11.7% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 31%. In 2026, NDAQ stock is down 8.9%, compared to the SPX’s 8.3% rise on a YTD basis.
More News from Barchart
Dear D-Wave Quantum Stock Fans, Mark Your Calendars for May 12 Berkshire Hathaway Just Upped Its Stake in Sumitomo Stock. Greg Abel Says It’s Holding for the Long Term. Stocks Settle Higher on Strong Earnings Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now!
Narrowing the focus, NDAQ’s underperformance looks less pronounced compared to SPDR S&P Capital Markets ETF (KCE). The exchange-traded fund has gained about 16.7% over the past year. Moreover, the ETF’s 2.3% returns on a YTD basis outshine the stock’s losses over the same time frame.www.barchart.com
On Apr. 23, NDAQ shares closed up marginally after reporting its Q1 results. Its adjusted EPS of $0.96 exceeded Wall Street expectations of $0.93. The company’s net revenue was $1.41 billion, topping Wall Street forecasts of $1.37 billion.
For the current fiscal year, ending in December, analysts expect NDAQ’s EPS to grow 10.9% to $3.86 on a diluted basis. The company’s earnings surprise history is impressive. It beat the consensus estimate in each of the last four quarters.
Among the 19 analysts covering NDAQ stock, the consensus is a “Strong Buy.” That’s based on 13 “Strong Buy” ratings, three “Moderate Buys,” and three “Holds.”www.barchart.com
This configuration is more bullish than three months ago, with 11 analysts suggesting a “Strong Buy.”
On Apr. 24, Michael Cho from JPMorgan Chase & Co. (JPM) maintained a “Buy” rating on NDAQ, with a price target of $111, implying a potential upside of 25.5% from current levels.
The mean price target of $109.65 represents a 23.9% premium to NDAQ’s current price levels. The Street-high price target of $128 suggests an ambitious upside potential of 44.7%.
On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com
View Comments
- Elliptic Secures $120 Million Investment From Nasdaq Ventures, Deutsche Bank, One Peak and the British Business Bank
May 12, 2026 · businesswire.com
NEW YORK--(BUSINESS WIRE)--Elliptic, the global leader in digital asset decisioning, today announced the closing of a $120 million Series D fundraise led by One Peak, with participation from Nasdaq Ventures, Deutsche Bank and the British Business Bank. The round values Elliptic at $670 million. These investors are among the most consequential institutions in global finance, together responsible for trillions in daily market activity, and they have placed their confidence in Elliptic. It is a si.
